Cancer | Dose of resveratrol | Duration of study | Number of patient | Outcome | Refs |
---|---|---|---|---|---|
CRC | 5Â g/day | 14Â days | 6 | Increase the cleaved caspase-3 in malignant hepatic tissue. | [88] |
0.5 or 1Â g/day | 8Â days | 20 | Decrease expression of Ki-67 | [31] | |
20 or 80Â mg/day | 2Â weeks | 8 | Inhibit the Wnt pathway | [100] | |
PC | 150Â mg or 1000Â mg/day | 4Â months | 66 | Decrease the serum levels of androgens with no alterations in prostate tumor growth | [95] |
4000Â mg/day | 14 | Safe | [94] | ||
MM | 5Â g/day | 21Â days | 24 | Unacceptable safety profile and minimal efficacy in patients with relapsed/refractory multiple myeloma highlighting the risks of novel drug development in such populations | [97] |
BC | 5 or 50 mg twice a day | 3 months | 39 | Reduce the methylation of RASSF-1α | [101] |